Explore 3 Stock Ideas & Industry Insights Download Free Report

Intellia Therapeutics Inc

Company price
9.85 USD -0.01 ( 0.10%)
Last update at 2026-11-17T18:06:00Z
VOLUME
2897185
Market Cap
1591.84M

Momentum Score

…

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.69
Low
10.24
High
52 Week Price Range
7.95
Low
28.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Intellia Therapeutics is a clinical-stage company developing CRISPR/Cas9 genome-editing therapies using in vivo and ex vivo delivery to treat genetic diseases. Long-term growth drivers include clinical progress of liver-directed and other programs, expansion of delivery technologies such as lipid nanoparticles, and pipeline growth into additional inherited and hepatic disorders that may benefit from one-time durable edits.

Key risks are clinical and regulatory uncertainty around safety and durability of edits, intense competition in gene editing, and ongoing cash needs that could require dilutive financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.86
Dividend Yield
-
Revenue TTM
59.51M
Revenue Per Share
0.50
Gross Profit TTM
-222.82M
Debt / Equity
0.14
ROE
-55.44%
Net Debt
-62.13M
ROCE
-55.90%
Diluted EPS TTM
-3.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -412.69M -519.02M -481.19M -474.19M -267.89M
Net income -412.69M -519.02M -481.19M -490.21M -259.72M
Selling general administrative 119.80M 125.83M 116.50M 90.31M 71.10M
Gross profit 51.75M 47.59M 27.30M 52.12M 33.05M
Reconciled depreciation 15.92M 10.29M 8.98M 7.57M 6.89M
Ebit -412.69M -519.02M -481.19M -458.16M -274.74M
Ebitda -396.77M -508.74M -472.22M -444.68M -267.85M
Depreciation and amortization 15.92M 10.29M 8.98M 13.48M 6.89M
Non operating income net other - - - -17.66M 0.04M
Operating income -440.99M -534.26M -515.29M -458.16M -267.85M
Other operating expenses 508.66M 592.14M 551.57M 510.29M 300.90M
Interest expense - - - 8.54M 6.89M
Interest income 29.20M 47.81M 49.83M 8.54M 1.28M
Net interest income 29.20M 47.81M 49.83M 8.54M 1.28M
Income tax expense - - -49.73M 16.02M -8.17M
Total revenue 67.67M 57.88M 36.27M 52.12M 33.05M
Total operating expenses 492.74M 581.86M 542.59M 510.29M 300.90M
Cost of revenue 15.92M 10.29M 8.98M - -
Total other income expense net 28.30M 15.24M 34.10M -16.02M -0.04M
Net income from continuing ops -412.69M -519.02M -481.19M -474.19M -267.81M
Net income applicable to common shares - - - -474.19M -267.89M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 842.13M 1191.02M 1300.98M 1520.11M 1294.46M
Other current assets 68.36M 29.83M 49.65M 20.41M 18.58M
Total liab 170.73M 319.06M 250.81M 284.53M 254.22M
Total stockholder equity 671.39M 871.96M 1050.17M 1235.58M 1040.24M
Other current liab 49.86M 55.35M 67.02M 60.88M 43.31M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -2590.09M -2177.40M -1658.38M -1177.19M -703.00M
Other liab - - - 43.96M 63.48M
Other assets - - - 15.73M 4.76M
Cash 155.46M 189.18M 226.75M 523.51M 123.41M
Total current liabilities 103.88M 110.85M 115.21M 126.55M 125.83M
Current deferred revenue 7.29M 20.66M 22.14M 43.84M 63.76M
Net debt -62.13M 21.02M -111.40M -392.80M -49.38M
Short term debt 26.48M 20.25M 18.60M 16.68M 9.11M
Short long term debt total 93.33M 210.20M 115.35M 130.70M 74.02M
Other stockholder equity 3260.44M 3048.74M 2710.80M 2420.22M 1745.87M
Property plant equipment - - - 27.92M 20.97M
Total current assets 527.71M 639.86M 998.33M 1216.80M 769.30M
Long term investments 190.79M 304.48M 154.51M 142.32M 425.05M
Net tangible assets - - - 1369.53M 1168.63M
Short term investments 294.42M 412.33M 685.48M 669.12M 625.28M
Net receivables 9.47M 8.52M 36.46M 3.77M 2.03M
Inventory - - - -69.34M -337.36M
Accounts payable 20.25M 14.59M 7.45M 5.15M 9.65M
Accumulated other comprehensive income 1.03M 0.60M -2.26M -7.46M -2.63M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -1177.19M -703.00M
Non currrent assets other 155.25M 260.21M - 72.98M 87.69M
Non current assets total 314.42M 551.15M 302.65M 303.32M 525.16M
Capital lease obligations 93.33M 210.20M 115.35M 130.70M 74.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 229.16M 125.57M -107.44M 160.31M -535.02M
Change to liabilities - - - 11.34M 17.79M
Total cashflows from investing activities 125.57M 125.57M -31.35M 160.31M -550.78M
Total cash from financing activities 185.75M 185.75M 130.32M 582.96M 736.69M
Change to operating activities - - - 15.91M 7.82M
Net income -519.02M -519.02M -481.19M -474.19M -267.89M
Change in cash -37.57M -37.57M -295.11M 409.98M -39.12M
Begin period cash flow 240.35M 240.35M 535.46M 125.49M 164.61M
End period cash flow 202.79M 202.79M 240.35M 535.46M 125.49M
Total cash from operating activities -348.88M -348.88M -394.09M -333.29M -225.03M
Issuance of capital stock 128.18M 176.90M 519.83M 565.79M 693.57M
Depreciation 10.29M 10.29M 8.98M 7.57M 6.89M
Other cashflows from investing activities 20.97M 0.00M - -44.68M -3.00M
Change to inventory - - -19.51M - 7.82M
Change to account receivables -0.95M 27.94M -32.69M -1.74M 0.10M
Sale purchase of stock - - - 582.96M 1861.02M
Other cashflows from financing activities 54.26M 8.85M 10.53M 17.17M 43.12M
Change to netincome - - - 171.79M 45.68M
Capital expenditures 5.78M 5.78M 13.98M 58.39M 12.76M
Change receivables - - - -1.74M 0.10M
Cash flows other operating - - - -52.07M -43.73M
Cash and cash equivalents changes - - - 409.98M -39.12M
Change in working capital -73.75M 11.88M -52.45M -53.87M -22.90M
Stock based compensation 154.27M 154.27M 134.05M 91.40M 47.01M
Other non cash items 79.33M -6.29M -3.47M 95.80M 2.94M
Free cash flow -354.66M -354.66M -408.07M -391.68M -237.79M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NTLA
Intellia Therapeutics Inc
-0.01
0.10%
9.85 - - 26.75 2.29 21.83 -5.51
NVO
Novo Nordisk A/S
-0.80
1.91%
40.80 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-2.08
0.39%
535.71 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
9.09
0.95%
961.49 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Intellia Therapeutics Inc

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

40 Erie Street, Cambridge, MA, United States, 02139

857 285 6200

377

Name Title Year Born
Dr. John M. Leonard M.D. Pres, CEO & Director 1957
Mr. Glenn G. Goddard CPA Exec. VP, CFO & Treasurer 1971
Dr. Laura Sepp-Lorenzino Ph.D. Exec. VP & Chief Scientific Officer 1961
Mr. James E. Basta Esq., J.D. Exec. VP, Gen. Counsel & Corp. Sec. 1966
Dr. David Lebwohl M.D. Exec. VP & Chief Medical Officer 1955
Mr. Nessan Bermingham Ph.D. Founder & Member of Scientific Advisor Board 1973
Dr. Rachel E. Haurwitz Ph.D. Co-Founder 1986
Dr. Andrew May Founder and Member of Scientific Advisor Board NA
Dr. Jennifer A. Doudna Ph.D. Founder & Member of Scientific Advisor Board 1964
Dr. Derrick J. Rossi Ph.D. Founder & Member of Scientific Advisor Board NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…